In reply —Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex

We thank Swenson and Del Parigi1 for their comments on our article.2 The article originally submitted on September 6, 2018. This formulation of amikacin inhalation (Arikayce) received Food and Drug Administration approval on September 28, 2018. Although we agreed that liposomal amikacin is an important therapeutic option for refractory mycobacterium avium complex pulmonary disease, at the time of our original submission we had included timely information on pages 1574 to 1575. Unfortunately, we did not have the Food and Drug Administration –approved dosage of Arikayce at the time of submission nor did the reviewers request us to include this information in Table 2 upon editing.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Letter to the editor Source Type: research